An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Insulin (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Oramed Pharmaceuticals
- 15 Sep 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.
- 03 Jun 2022 Planned primary completion date changed from 1 May 2022 to 1 Jun 2022.